Chapin Davis Inc. acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 825 shares of the biopharmaceutical company’s stock, valued at approximately $200,000.
Several other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after buying an additional 287,064 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 12,513 shares during the last quarter. Quattro Financial Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 2,517.8% during the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after acquiring an additional 4,809 shares during the period. Westpac Banking Corp grew its position in shares of Alnylam Pharmaceuticals by 59.8% in the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 566 shares during the last quarter. Finally, Plato Investment Management Ltd increased its stake in shares of Alnylam Pharmaceuticals by 2,666.3% in the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after purchasing an additional 4,346 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Price Performance
ALNY opened at $269.28 on Monday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $274.93. The company’s 50 day simple moving average is $232.23 and its 200-day simple moving average is $180.32. The stock has a market capitalization of $34.06 billion, a P/E ratio of -100.09 and a beta of 0.37.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on ALNY shares. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. TD Cowen raised their price objective on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. UBS Group upped their target price on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a research note on Friday, June 28th. HC Wainwright reissued a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Finally, Evercore ISI boosted their price objective on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, June 25th. Seven analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $277.14.
Read Our Latest Stock Analysis on ALNY
Insider Buying and Selling at Alnylam Pharmaceuticals
In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the transaction, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now directly owns 136 shares of the company’s stock, valued at $35,632. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the sale, the chief executive officer now owns 80,534 shares in the company, valued at $18,602,548.66. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 109,848 shares of company stock valued at $24,683,444. 1.50% of the stock is currently owned by insiders.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Featured Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- Ride Out The Recession With These Dividend KingsĀ
- 3 Affordable Stocks Under $10 Ready to Rebound Soon
- CD Calculator: Certificate of Deposit Calculator
- The Rebound is on for Applied Materials Stock PriceĀ
- Best Stocks Under $10.00
- Archer Aviation Stumbles on Q2 Earnings, But Potential Remains
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.